<div><p><strong>Protein purification is a critical step in biopharmaceutical research, proteomics, and industrial biotechnology. It involves isolating a specific protein from complex biological mixtures while preserving its native structure and activity. Traditional methods such as precipitation or dialysis lack the precision required for high-purity protein isolation, especially when dealing with therapeutic targets or complex protein assemblies.</strong></p><p>High-performance liquid chromatography (HPLC) protein purification has transformed this field by providing high resolution, reproducibility, and speed, making it indispensable for both analytical and preparative workflows.</p></div><div><div><div><div><h3><strong>What is HPLC Protein Purification?</strong></h3><p>HPLC purification is based on the principle of selective interactions between proteins and the stationary phase under high-pressure liquid flow. The separation relies on differences in size, charge, hydrophobicity, or affinity of proteins toward the stationary phase material.</p><p>Unlike conventional low-pressure methods such as gel filtration or affinity batch purification, HPLC purification operates under high pressure (up to 6000 psi), enabling faster separation with enhanced resolution and quantitative recovery. It also offers precise control over parameters like gradient composition, pH, and temperature, minimizing variability between runs.</p><p>In contrast to traditional column chromatography, HPLC uses smaller stationary phase particles (3–10 µm), resulting in increased surface area and sharper <a target="_blank" rel="noopener noreferrer" href="https://www.phenomenex.com/resources/knowledge-center/hplc-knowledge-center/how-to-reduce-peak-tailing-in-hplc"><strong>peak shapes</strong></a>, which are vital for protein purity assessment and scale-up purification.</p></div></div></div></div><div><div><div><div><h3><strong>Types of HPLC Used for Protein Purification</strong></h3></div></div></div></div><div><p>Different HPLC modes can be employed depending on the physicochemical properties of the target protein. Each method offers unique advantages in terms of selectivity and recovery.</p><h4><strong>Reversed-Phase HPLC (RP-HPLC)</strong></h4><p><a target="_blank" rel="noopener noreferrer" href="https://www.phenomenex.com/techniques/hplc-reversed-phase"><strong>Reversed-Phase HPLC</strong></a> separates proteins based on hydrophobic interactions between the analyte and the stationary phase, typically C4, C8, or C18 silica-based columns. Proteins are eluted using gradients of organic solvents (usually acetonitrile or methanol) in the presence of volatile acids like formic or trifluoroacetic acid (TFA).</p><p>This method provides exceptional resolution and is commonly used for protein fragment purification, and analysis of recombinant proteins. For example, reversed-phase HPLC is routinely employed in peptide therapeutic workflows, such as the<a target="_blank" rel="noopener noreferrer" href="https://lcms.labrulez.com/labrulez-bucket-strapi-h3hsga3/an59280424_w_fc6c3ac6f0.pdf"><strong> Tirzepatide Preparation and Purification </strong></a>process, where purity and recovery are critical to product efficacy. However, due to exposure to organic solvents, RP-HPLC may cause partial denaturation, limiting its use for native proteins.</p><h4><strong>Ion Exchange HPLC (IEX-HPLC)</strong></h4><p><a target="_blank" rel="noopener noreferrer" href="https://www.phenomenex.com/techniques/hplc-sec"><strong>IEX-HPLC</strong></a> separates proteins based on net surface charge. Cation exchange (with negatively charged stationary phases) binds positively charged proteins, while anion exchange does the reverse.</p><p>By gradually increasing salt concentration or changing the mobile phase pH, proteins are eluted according to their isoelectric points (pI).By gradually increasing salt concentration or changing the mobile phase pH, proteins are eluted according to their isoelectric points (pI).</p><p>This approach is highly suitable for native purification, protein isoform analysis, and charge variant characterization essential steps in therapeutic protein production.</p><h4><strong>Size Exclusion Chromatography (SEC-HPLC)</strong></h4><p>SEC separates molecules based on their hydrodynamic radius. Larger proteins elute first, as they are excluded from the pores of the stationary phase, while smaller molecules penetrate and elute later.</p><p><a target="_blank" rel="noopener noreferrer" href="https://www.phenomenex.com/techniques/hplc-sec"><strong>SEC-HPLC</strong></a> is non-denaturing and ideal for determining protein molecular weight, oligomeric state, and aggregate content. It is frequently used as a final polishing step following ion exchange or affinity chromatography.</p><h4><strong>Affinity HPLC</strong></h4><p>Affinity-based HPLC leverages specific biological interactions between the target protein and a ligand immobilized on the stationary phase (e.g., antibodies, metal ions, or tags such as His-tag or GST).</p><p>When integrated into an HPLC system, affinity chromatography provides high selectivity and purity (&gt;95%) in a single step, often used in recombinant protein purification and biomarker capture applications.</p></div><div><div><div><div><h3><strong>Benefits of Using HPLC for Protein Purification</strong></h3><p>HPLC-based protein purification combines the analytical precision of chromatography with the preparative capability needed for research and biomanufacturing. The main advantages include:</p><h5><strong>Benefit &nbsp;/ &nbsp;Description</strong></h5><p><strong>High Resolution and Selectivity:</strong></p><ul><li>Smaller stationary phase particles and optimized flow dynamics allow HPLC to resolve proteins differing by minimal physicochemical properties. This precision is vital for distinguishing isoforms, mutants, and post-translationally modified variants.</li></ul><p><strong>Accuracy and Reproducibility</strong></p><ul><li>Automated systems maintain stable flow rates, gradient control, and detection sensitivity, ensuring reproducible results essential for regulated biopharmaceutical workflows.</li></ul><p><strong>Speed and Efficiency</strong></p><ul><li>Modern UHPLC systems equipped with fully porous or core–shell particles achieve faster separations without sacrificing resolution, reducing run times by up to 50% compared to classical methods.</li></ul><p><strong>Compatibility and Scalability</strong></p><ul><li>HPLC systems are highly adaptable, supporting both analytical-scale characterization and preparative-scale purification. Methods developed at microgram scale can be seamlessly transferred to milligram or gram scales used in process development.</li></ul><div><div><div><div><h3><strong>Factors Affecting the Efficacy of Protein Purification by HPLC</strong></h3></div></div></div></div><div><p>Optimizing HPLC for protein purification requires balancing purity, recovery, and throughput. The following parameters significantly influence results:</p><ul><li><strong>Purification goal:</strong> Define whether the priority is yield, purity, or throughput. Analytical separations prioritize resolution, while preparative runs emphasize recovery and process speed.</li><li><strong>Protein solubility and stability:</strong> Unstable or aggregation-prone proteins may require low temperatures or additives (e.g., glycerol, mild detergents).</li><li><strong>Column chemistry and particle size:</strong> Select appropriate stationary phase chemistry (silica, polymeric, or mixed-mode) and particle size to suit molecular weight and hydrophobicity.</li><li><strong>Mobile phase pH and ionic strength:</strong> pH should be optimized near but not at the protein’s pI; salt gradients influence both resolution and elution strength.</li><li><strong>Flow rate and gradient profile:</strong> Steeper gradients shorten run time but may compromise separation quality.</li><li><strong>Purified protein final form:</strong> Consider buffer composition and concentration for storage or downstream assays to maintain bioactivity.</li></ul></div><div><div><div><div><h3><strong>Best Practices for Protein Purification by HPLC</strong></h3></div></div></div></div><div><p>Following good chromatographic practices ensures consistent, high-quality results:</p><ul><li><strong>Column conditioning and storage:</strong> Always equilibrate new <a target="_blank" rel="noopener noreferrer" href="https://lcms.labrulez.com/products?category=48&amp;manufacturerItems=50"><strong>HPLC columns</strong></a> with 10 column volumes of buffer; store in appropriate solvent containing preservatives.</li><li><strong>Avoid protein precipitation:</strong> Maintain appropriate ionic strength and, when native state is desired, avoid exposure to denaturing solvents or high organic content.</li><li><strong>Prevent sample loss:</strong> Use low-protein-binding tubing and vials; minimize dead volume in the system.</li><li><strong>Troubleshooting:</strong><ul><li>Peak fronting - may indicate column overloading.</li><li>Peak broadening – may indicate column channeling.</li><li>Carryover – reduce by extending wash cycles or using stronger regeneration solvents.</li><li>Clogging – prefilter samples (0.22 µm) and periodically flush the system.</li></ul></li></ul></div></div></div></div></div>

Protein Purification by HPLC: Methods, Benefits, and Best Practices

<p><strong>Scientists from CEITEC Brno University of Technology&nbsp;have succeeded in a highly competitive international selection process and secured a prestigious Human Frontier Science Program (HFSP) grant, which supports groundbreaking fundamental research. The Brno-based team led by Eric Daniel Glowacki will contribute a unique technology to an international project that enables precise control of oxygen levels in tissues. Changes in oxygen availability may play a crucial role in determining how cells specialize during early embryonic development.</strong></p><p>The project, entitled “Beyond Theory: Regulation of Mammalian Embryo Patterning by Electrochemical Gradients,” is being carried out by CEITEC BUT in collaboration with biologists from the <strong>Max Planck Institute of Molecular Cell Biology and Genetics</strong> and <strong>Yale University</strong>. The Brno team’s role is central to the project: providing technology that enables the deliberate creation of regions with different oxygen concentrations in tissues and the observation of how cells respond to these changes.</p><p><i>“Our research group specializes in electrochemistry, particularly in studying how electric current affects tissue oxygenation and the resulting chemical changes. To perform certain types of experiments, we developed our own integrated system of needle probes, electrodes, and software, which allows us to influence and control the amount of oxygen present in tissues through which current is passed,” </i>explains team leader <strong>Eric Daniel Glowacki</strong>. Using these tools, researchers can create regions within samples where oxygen is scarce or even completely absent. Changes in oxygen levels are fundamental to biology because they affect cellular metabolism and, consequently, cell behaviour. In some types of research, such precise environmental control is essential.</p><p><i>“Our system is not universal; we tailor it to each application. In the future, however, we aim to expand its variants so that it can be used across the widest possible range of research fields,”</i> adds Eric.</p><p>Scientists at the Max Planck Institute have already used CEITEC’s technology in previous studies of early embryonic development. They investigated how the metabolic activity of stem cells – undifferentiated cells capable of self-renewal and transformation into specialized cells such as muscle, nerve, or blood cells – affects both their own development and that of neighbouring cells.</p><p>The newly funded HFSP project builds on this work. Its goal is to revisit the nearly century-old theory&nbsp;proposed by the American zoologist Charles Manning Child, which explains how stem cells in multicellular organisms gradually develop into mature cells with specific functions and structures. The three-year project, supported by a grant of<strong> CZK 7.5 million </strong>for each partner, will test a new hypothesis in mouse embryos directly in the uterus: that the specific transformation of cells depends not only on oxygen depletion itself but also on the cell’s location within the tissue and the timing of the oxygen decrease.</p><p><img src="https://storage.googleapis.com/labrulez-bucket-strapi-h3hsga3/CEITEC_Technologie_vedcu_z_CEITEC_pomuze_odhalit_jak_kyslik_ridi_vyvoj_embryi_2_1ea86be296.jpeg" alt="CEITEC/ Lukáš Havlák: CEITEC Technology Will Help Reveal How Oxygen Controls Embryo Development: HFSP technological setup at CEITEC BUT." srcset="https://storage.googleapis.com/labrulez-bucket-strapi-h3hsga3/thumbnail_CEITEC_Technologie_vedcu_z_CEITEC_pomuze_odhalit_jak_kyslik_ridi_vyvoj_embryi_2_1ea86be296.jpeg 235w," sizes="100vw" width="1600" height="1067"></p><p>A better understanding of the mechanisms that govern early embryonic development could, in the future, contribute to advances in regenerative medicine, research into developmental disorders, and the more effective use of stem cells in biomedicine.</p><p><i>“The success of our project is both a great honour and a significant responsibility. HFSP is a unique programme dedicated to fundamental research, where investigators seek answers to the most basic and still unresolved questions in biology,”</i> says Eric. The programme is extremely competitive, with only two to three percent of the thousands of submitted projects receiving funding. Requirements include international collaboration across continents and a genuinely innovative approach.</p><p><i>“Through this, we have become part of a community of world-class scientists from around the globe. Although the results of this kind of research are not immediately applicable, their long-term benefit to society is immense,” </i>Eric concludes.</p><blockquote><h4><strong>About HFSP</strong></h4><p>The Human Frontier Science Program Organization (HFSPO) was established in France in 1989, although the idea of creating such an international community dedicated to fundamental research originated several years earlier in Japan. The programme funds cutting-edge research in life sciences, particularly in biology, physics, chemistry, mathematics, and computer science, and supports innovative interdisciplinary projects that would otherwise be difficult to finance.</p><p>HFSPO receives funding from governments and institutions, including those of France, Japan, Switzerland, South Korea, the United States, the European Union, Singapore, New Zealand, and the United Kingdom. Since the programme’s launch in 1989, 31 HFSP-supported scientists have gone on to receive Nobel Prizes. The most recent awardees, in 2024, were David Baker, who received the Nobel Prize in Chemistry for computational protein design, and Gary Ruvkun, who received the Nobel Prize in Physiology or Medicine for the discovery of microRNA.</p></blockquote>

CEITEC Technology Will Help Reveal How Oxygen Controls Embryo Development

<p><strong>🎤Rajas Poorna and Charles Anderson</strong></p><h4><strong>What if you could dry biofluid samples in the field—without a vacuum system, freeze dryer, or full lab setup?</strong></h4><p>In this episode of Concentrating on Chromatography, I sit down with Rajas Poorna and Charles Anderson to explore their work on a frugal, field-deployable alternative to traditional lyophilization through the Evapinator project.</p><p>Originally inspired by the principles of frugal science, their approach rethinks how we stabilize and prepare biofluid samples like blood and plasma—especially in environments where traditional lab infrastructure simply isn’t available.</p><h4><strong>What This Episode Covers:</strong></h4><h5><strong>A Frugal Take on Lyophilization</strong></h5><p>Can you replicate the outcome of a lyophilizer without the complexity?<br>Why traditional freeze drying is often too expensive and impractical for field use<br>How simplifying evaporation could unlock entirely new workflows</p><h5><strong>Drying Biofluids in the Field</strong></h5><p>The real-world challenge of handling blood and other biofluids outside the lab<br>Why sample stability during transport is such a critical bottleneck<br>How a portable system could enable on-site sample prep in remote or resource-limited settings</p><h5><strong>Rethinking Evaporation (No Vacuum Required)</strong></h5><p>The core idea behind the Evapinator—and how it challenges conventional assumptions<br>The role of airflow, heat, and design in drying sensitive samples<br>Where this approach fits relative to traditional evaporation and lyophilization techniques</p><h5><strong>Early Results &amp; Practical Insights</strong></h5><p>What’s working so far—and where limitations still exist<br>The types of applications where this approach shows the most promise<br>What still needs to be validated in upcoming peer-reviewed work</p><h4><strong>Why This Matters</strong></h4><p>From clinical research in remote regions to decentralized diagnostics, the ability to dry and preserve biofluid samples in the field could fundamentally change how and where analysis happens.</p><p>This conversation challenges a core assumption in analytical science:</p><p>Do you really need a full lyophilizer—or even a vacuum—to stabilize biofluid samples?</p><h3><strong>Video Transcription</strong></h3><p>The interview opens with a welcome to an episode of <i>Concentrating on Chromatography</i>. The host introduces guests <strong>Rajas Poorna</strong> and <strong>Charles Anderson</strong> and asks about their scientific backgrounds and how they became involved in solving evaporation challenges.</p><h4><strong>Scientific background and project origin</strong></h4><p>Rajas explains that he is trained as a physicist and is now pursuing a PhD in bioengineering. His lab focuses on building low-cost scientific equipment to make science more accessible, especially for schools and low-resource settings. This work is part of a broader “frugal science” approach, where students and researchers develop affordable versions of instruments that are normally expensive.</p><p>The original challenge came from synthetic biology education. High school teams working on synthetic biology projects needed access to equipment such as lyophilizers, but conventional systems can cost tens of thousands of dollars. The team therefore began exploring whether a more affordable lyophilizer-like system could be built for education and field use.</p><p>Charles describes joining the project early in his undergraduate studies. He was drawn to it because it had a clear practical purpose and seemed like something that could become useful outside the laboratory rather than remaining only a research prototype.</p><h4><strong>Why evaporation became the key challenge</strong></h4><p>The discussion turns to the practical limitations of traditional evaporation and drying systems. Rajas explains that during a collaboration in Thailand, researchers working on Raman spectroscopy for tuberculosis diagnostics needed to dry blood-derived samples before transporting them to a central laboratory. They used a centrifugal vacuum evaporator, but the system was slow, expensive, and difficult to service when it broke down.</p><p>This experience led to a central question: could sample drying be achieved without a vacuum? Rajas notes that everyday drying processes, such as drying clothes, do not require vacuum. This insight opened the path toward a simpler, smaller, lower-cost and potentially battery-powered drying system.</p><h4><strong>How Rajas and Charles began collaborating</strong></h4><p>Charles explains that he met the lab’s principal investigator while discussing a different project. He was then invited to work on what would later become the Evaponator. At the beginning, the project was still small and exploratory.</p><p>Rajas adds that Charles joined at a stage when the team was trying to understand the physics and engineering behind vacuum-free drying. Within a few months, they developed a prototype costing under 100 USD that could dry samples much faster than the conventional vacuum evaporator used by collaborators.</p><h4><strong>Main limitations of conventional drying systems</strong></h4><p>The interview identifies several major limitations of existing evaporation technologies:</p><ul><li>High cost</li><li>Limited reliability in remote or low-resource settings</li><li>Long drying times</li><li>Poor field portability</li><li>Challenges with sterility and cross-contamination</li></ul><p>Charles emphasizes that freeze drying can take 12–24 hours, which is impractical for field use. Rajas adds that centrifugal vacuum evaporators are not necessarily sterile and may pose a risk of cross-sample contamination. Together, these challenges shaped the requirements for the Evaponator.</p><h4><strong>What the Evaponator is</strong></h4><p>Charles introduces the Evaponator as a low-cost, portable drying system designed to dry small numbers of samples quickly without a vacuum chamber. The name was inspired by an episode of <i>Phineas and Ferb</i>.</p><p>The system is based on the same principles as drying clothes: low humidity, gentle heating and airflow. Instead of using vacuum, the Evaponator generates dry air, directs it over the sample, removes moisture through a cold trap and repeats the process in a closed or semi-closed loop.</p><p>The current design is aimed at drying approximately four 1 ml samples, which fits the intended use case of field diagnostics or low-throughput sample collection in remote settings.</p><h4><strong>How the system works</strong></h4><p>Rajas explains the operating principle in more detail. Moist air is passed through a cooled metal block using a thermoelectric cooler. As the air cools, moisture condenses inside the cold trap, producing dry air. This dry air is then directed over warmed samples, helping water evaporate while keeping the sample temperature moderate.</p><p>The system can operate in a loop to improve efficiency. HEPA filtration and aerosol filtration help prevent contamination. The team also developed an ozone-based sterilization approach, allowing the device to sterilize itself using ozone generated from air rather than relying on consumables such as ethanol or peroxide.</p><p>To prevent sample-to-sample contamination, the design uses separate airflow paths for individual samples, which merge only later in the system.</p><h4><strong>Design assumptions and engineering constraints</strong></h4><p>A key design assumption is that not every drying process needs sublimation or deep vacuum. For the biofluid applications targeted by the Evaponator, the team works around 40 °C, a temperature chosen because it is close to fever temperature and should be mild enough for many biological samples.</p><p>The engineering constraints included:</p><ul><li>Use of widely available components</li><li>No specialized machining</li><li>Bill of materials under 100 USD</li><li>Low power consumption</li><li>Portability</li><li>Simple assembly</li><li>Robust airflow without splashing or sample loss</li></ul><p>Charles notes that the team intentionally selected accessible parts, including components similar to those used in computer cooling systems, vacuum-cleaner-style HEPA filters and disposable pipette tips for directing airflow.</p><h4><strong>Sample types and solvents</strong></h4><p>The prototype is currently focused mainly on aqueous biological samples. Rajas explains that using organic solvents such as ethanol would introduce ignition risks with the current architecture, so the early work is focused on water-based samples and biofluids.</p><p>Charles adds that the system is intended primarily for blood-derived fluids, urine, saliva and similar samples where the target analytes can remain stable after drying and rehydration.</p><h4><strong>Potential analytical applications</strong></h4><p>The Evaponator is being developed for field sample preparation rather than as a replacement for every laboratory evaporator. The main idea is to dry samples near the point of collection, transport them more easily and then rehydrate them before analysis.</p><p>Potential use cases include:</p><ul><li>Field diagnostics</li><li>Biofluid sample stabilization</li><li>Remote sample collection</li><li>Clinical or public-health testing in low-resource settings</li><li>Applications where dried plasma, serum, urine or saliva can later be analyzed</li><li>Situations where conventional dried blood spot methods lack enough sample volume</li></ul><p>Rajas notes that red blood cells may not be suitable for drying directly because they can rupture, so serum or plasma is expected to be more appropriate. He also points out that oxygen exposure during forced-air drying still needs further testing for oxygen-sensitive analytes.</p><h4><strong>Current development status</strong></h4><p>Charles explains that the project is approaching important validation milestones, especially around batch-to-batch and sample-to-sample sterility. The ozone cleaning system appears promising because it may reduce the need for cleaning consumables, aside from inexpensive items such as pipette tips and occasional filter replacement.</p><p>He also mentions tests with trehalose-based solutions and collaboration with a Georgia Tech startup working on room-temperature-stable mRNA vaccines. In that context, the Evaponator was able to dry samples in about 30 minutes, compared with 12–24 hours using previous drying approaches.</p><h4><strong>Commercialization and future direction</strong></h4><p>Rajas explains that the team is exploring commercialization and has participated in a startup accelerator. They are investigating where the technology could have the strongest product-market fit, with particular interest from cost-sensitive and geographically dispersed healthcare settings, including India.</p><p>The goal is to move beyond a lab prototype toward a manufacturable, user-friendly device with a straightforward interface and reliable sealing, sterilization and operation.</p><h4><strong>Closing remarks</strong></h4><p>The interview concludes with the host thanking Rajas Poorna and Charles Anderson for sharing the technical and practical challenges behind the Evaponator. Both guests emphasize that the conversation was a valuable opportunity to explain the project in depth and reflect on its progress.</p><blockquote><p><strong>This text has been automatically transcribed from a video presentation using AI technology. It may contain inaccuracies and is not guaranteed to be 100% correct.</strong></p></blockquote><blockquote><h4><strong>Concentrating on Chromatography Podcast</strong></h4><p>Dive into the frontiers of chromatography, mass spectrometry, and sample preparation with host David Oliva. Each episode features candid conversations with leading researchers, industry innovators, and passionate scientists who are shaping the future of analytical chemistry. From decoding PFAS detection challenges to exploring the latest in AI-assisted liquid chromatography, this show uncovers practical workflows, sustainability breakthroughs, and the real-world impact of separation science. Whether you’re a chromatographer, lab professional, or researcher you'll discover inspiring content!</p><p>You can find <strong>Concentrating on Chromatography Podcast </strong>in podcast apps:</p><ul><li><a target="_blank" rel="noopener noreferrer" href="https://open.spotify.com/show/1wZg67rCjoGju4yhqxI3tL"><strong>Spotify</strong></a></li><li><a target="_blank" rel="noopener noreferrer" href="https://podcasts.apple.com/tz/podcast/concentrating-on-chromatography/id1788429185"><strong>Apple podcast</strong></a></li><li><a target="_blank" rel="noopener noreferrer" href="https://podscan.fm/podcasts/concentrating-on-chromatography"><strong>podscan</strong></a></li></ul><p>and on <a target="_blank" rel="noopener noreferrer" href="https://www.youtube.com/@ChromatographyTalk/videos"><strong>YouTube channel</strong></a></p></blockquote>

Frugal Science Meets Sample Prep: A Field-Ready Lyophilizer for Biofluids

Article

Product

Academy

Video

Scientists

Interview

Science and research

Since its establishment in 2011, CEITEC has quickly developed into a cutting-edge infrastructure for research which performs highly alongside the best institutes in Europe. Among the main priorities of CEITEC are the promotion of a motivating and dynamic international scientific environment, the provision of state-of-the-art research infrastructure, and the policy of open communication and equal opportunities.

CEITEC

Phenomenex is a global technology leader committed to developing novel analytical chemistry solutions that solve the separation and purification challenges of researchers in industrial, government and academic laboratories.

Phenomenex

Organomation, founded in 1959, designs and manufactures high-quality nitrogen evaporators and extraction systems. Known for innovation and durability, their lab instruments are used globally for efficient sample preparation with strong customer support.

Organomation

Separation Science

Merck

Agilent Technologies

Wiley

VWR/Avantor

SCIEX

Evosep Biosystems

Waters Corporation

<p><strong>N-linked glycosylation is a critically important and complex post-translational modification.</strong></p>
<p><strong>The structure of N-linked glycans can influence the function of glycosylated biotherapeutics, making the characterization of N-glycans an essential part of the therapeutic development process.</strong></p>
<p>In this The Lab Central Premiere, learn about Agilent&#39;s complete offering of glycan sample preparation and analysis consumables to support a comprehensive end-to-end N-glycan workflow solution.</p>
<blockquote>
<p><strong>Presenter:</strong> Dr. Ashish Pargaonkar (Lead for Biopharma Workflow Commercialization, Agilent Technologies)</p>
</blockquote>
<blockquote>
<p><strong>Presenter:</strong> Ms. Paramjeet Khandpur (Biopharma Workflow Commercialization Lead, Agilent Techologies)</p>
</blockquote>


Agilent Technologies: The Glycan Connection

The Glycan Connection

Learn about Agilent's complete offering of glycan sample preparation and analysis consumables to support a comprehensive end-to-end N-glycan workflow solution.

<p><strong>This online event has been designed for our customers and brings together opinion leaders, top scientists and industry innovators to share their research in the biopharma field.</strong></p>
<p>The technologies presented will be CE and LC-MS.</p>
<p>Agenda:</p>
<h5><strong>10:00–10:10 Welcome and introduction</strong></h5>
<ul>
<li>Steve Lock, SCIEX</li>
</ul>
<h5><strong>10:10–10:35 Use of LC-MS in process analytical testing as part of development of a continuous manufacturing workflow</strong></h5>
<ul>
<li>Daniel Myatt / Ronan Gough, CPI</li>
</ul>
<h5><strong>10:35–11:00 Tips and tricks for biotherapeutics characterization by peptide mapping</strong></h5>
<ul>
<li>Giulia Calloni, SCIEX</li>
</ul>
<h5><strong>11:00–11:25 Developing methods for SEC-MS and IEX-MS for the analysis of biotherapeutics</strong></h5>
<ul>
<li>Sarah Nguyen, Strasbourg University</li>
</ul>
<h5><strong>11:25–11:35</strong> Break</h5>
<h5><strong>11:35–12:00 The power of CZE analysis for characterization of NANOBODY® molecules</strong></h5>
<ul>
<li>Dries Dejaegere, Sanofi</li>
</ul>
<h5><strong>12:00–12:25 Multi-capillary gel electrophoresis to increase throughput for the purity analysis of biotherapeutic proteins</strong></h5>
<ul>
<li>Theresa Merlino, The Janssen Pharmaceutical Companies of Johnson &amp; Johnson</li>
</ul>
<h5><strong>12:25–12:50 A disruptive approach to the characterization of mAb charge variants during biopharmaceutical process development</strong></h5>
<ul>
<li>Greg Adams, FUJIFILM</li>
</ul>
<h5><strong>12:50–13:00 Wrap-up and Q&amp;A</strong></h5>
<blockquote>
<p><strong>Presenter:</strong> Steve Lock, PhD (Snr. Marketing and Market Development Manager, Biopharma, EMEAI, SCIEX)</p>
</blockquote>
<blockquote>
<p>Steve obtained his PhD in Physical Organic Chemistry from the University College of Swansea in 1993 and is a chartered chemist and a member of the Royal Society of Chemistry. He has worked for SCIEX in various technical roles for over 20 years and has presented at over 80 international meetings around the world. He currently works closely with customers in the biopharmaceutical industry. Steve is also currently an Adjunct Professor at the University of Pannonia.</p>
</blockquote>
<p><img src="https://storage.googleapis.com/labrulez-bucket-strapi-h3hsga3/SCIEX_agenda_day_1_6818ee0331/SCIEX-agenda-day-1.jpg" alt="SCIEX - agenda day 1.jpg"/></p>


SCIEX: SCIEX Biopharma meeting - 3rd edition! Day 1 - Gene therapy, vaccines and oligonucleotides

SCIEX Biopharma meeting (Day 1) - Gene therapy, vaccines and oligonucleotides

Gene therapy, vaccines and oligonucleotides. The technologies presented will be CE and LC-MS.

Day 1 - Gene therapy, vaccines and oligonucleotides

<p><strong>This online event has been designed for our customers and brings  together opinion leaders, top scientists and industry innovators to share their research in the biopharma field.</strong></p>
<p>The technologies presented will be CE and LC-MS.</p>
<p>Agenda:</p>
<h5><strong>10:00–10:10 Welcome and introduction</strong></h5>
<ul>
<li>Steve Lock, SCIEX</li>
</ul>
<h5><strong>10:10–10:35 Particle seizing by CE</strong></h5>
<ul>
<li>Hervé Cottet, Montpellier University</li>
</ul>
<h5><strong>10:35–11:00 Application of CE for purity analysis in cell and gene therapy</strong></h5>
<ul>
<li>Ryan Hylands / Luiza Chrojan, Pharmaron</li>
</ul>
<h5><strong>11:00–11:25 Tips and tricks for success in CE analysis</strong></h5>
<ul>
<li>Whitney Smith, SCIEX</li>
</ul>
<h5><strong>11:25–11:35</strong> Break</h5>
<h5><strong>11:35–12:00 RNA payload analysis: development and analytical challenges</strong></h5>
<ul>
<li>Jérémie Parot, SINTEF Industry</li>
</ul>
<h5><strong>12:00–12:25 The use of CE for AAV analytics</strong></h5>
<ul>
<li>Padraig Flaherty, MeiraGTx</li>
</ul>
<h5><strong>12:25–12:50 Oligo analysis by LC-MS</strong></h5>
<ul>
<li>Alexandra Bushby, Labcorp</li>
</ul>
<h5><strong>12:50–13:00 Wrap-up and Q&amp;A</strong></h5>
<blockquote>
<p><strong>Presenter:</strong> Steve Lock, PhD (Snr. Marketing and Market Development Manager, Biopharma, EMEAI, SCIEX)</p>
</blockquote>
<blockquote>
<p>Steve obtained his PhD in Physical Organic Chemistry from the University College of Swansea in 1993 and is a chartered chemist and a member of the Royal Society of Chemistry. He has worked for SCIEX in various technical roles for over 20 years and has presented at over 80 international meetings around the world. He currently works closely with customers in the biopharmaceutical industry. Steve is also currently an Adjunct Professor at the University of Pannonia.</p>
</blockquote>
<p><img src="https://storage.googleapis.com/labrulez-bucket-strapi-h3hsga3/SCIEX_agenda_day_2_b442145213/SCIEX-agenda-day-2.jpg" alt="SCIEX - agenda day 2.jpg"/></p>


SCIEX: SCIEX Biopharma meeting - 3rd edition! Day 2 - Therapeutic proteins and peptides

SCIEX Biopharma meeting (Day 2) - Therapeutic proteins and peptides

Therapeutic proteins and peptides. The technologies presented will be CE and LC-MS.

Day 2 - Therapeutic proteins and peptides

<p><strong>Oligonucleotide analysis is a critical aspect of molecular biology and therapeutic development, demanding robust and versatile chromatographic techniques for comprehensive characterization.</strong></p>
<p>Several modes of chromatography can be employed to characterize these biomolecules, but when and how to best use each mode can be challenging.</p>
<p>This webinar aims to explore how various chromatographic techniques can be synergistically employed to achieve comprehensive oligonucleotide characterization. Aspects of ion-pair reversed phase chromatography (IP-RPC), hydrophilic interaction liquid chromatography (HILIC), ion exchange chromatography (IEC), and size exclusion chromatography (SEC) will be discussed and how best to employ each mode in oligonucleotide characterization. Several application examples will be utilized to showcase how each of these modes of chromatography can be best utilized to fully resolve and understand the composition of samples containing oligonucleotides.</p>
<p>At the conclusion of the webinar, the audience member will:</p>
<ul>
<li><p><strong>Understand the strengths and weaknesses of each mode of chromatography in characterizing oligonucleotides.</strong></p>
</li>
<li><p><strong>Be familiar with key method parameters to adjust when fine-tuning oligonucleotide chromatographic assays</strong></p>
</li>
<li><p><strong>Gain an appreciation for when to use each mode of chromatography when analyzing oligonucleotides</strong></p>
</li>
</ul>
<blockquote>
<p><strong>Presenter:</strong> Cory E. Muraco (Biomolecule Workflows Manager, Merck KGaA, Darmstadt, Germany)</p>
</blockquote>
<blockquote>
<p>Cory joined the company in 2013, starting in the Chemical Standards division, developing and validating analytical methods for testing the purity of certified reference materials using GC and LC methods. In 2022, Cory assumed his present role, where he is tasked with supporting the design, development, and execution of the marketing and R&amp;D strategies around bioanalytical strategy.</p>
</blockquote>
<blockquote>
<p><strong>Presenter:</strong> Andrea Krumm (Product Manager, Analytical Columns, Tosoh Bioscience GmbH)</p>
</blockquote>
<blockquote>
<p>Andrea Krumm studied biotechnology before gaining a PhD in Cell and Cancer Biology. After four years as an applications specialist for optical analytical devices used in academic and pharmaceutical research, she joined Tosoh Bioscience GmbH in 2020 as a product manager for analytical columns. Andrea is responsible for gathering customer requirements, application areas and addressing these with new and existing products of the analytical columns line.</p>
</blockquote>


Merck: Exploring Oligonucleotide Diversity: Insights From Multiple Modes of Chromatography

Exploring Oligonucleotide Diversity: Insights From Multiple Modes of Chromatography

How various chromatographic techniques can be synergistically employed to achieve comprehensive oligonucleotide characterization.

Oligonucleotide Diversity: Multiple Modes of Chromatography

<p><strong>In this webinar, our expert speakers will focus on the Karl Fischer titration process, quality assurance, and relevant regulations such as pharmacopeias to improve application accuracy.</strong></p>
<p>It will be of particular interest to people developing Karl Fischer applications or qualifying Karl Fischer titrations, especially lab technicians, lab managers, and quality control or assurance managers.</p>
<p>By attending this webinar, you will gain insight into the following:</p>
<ul>
<li><p><strong>Overview of the Karl Fischer titration process</strong></p>
</li>
<li><p><strong>Tips to optimize your Karl Fischer application performance</strong></p>
</li>
<li><p><strong>How to fulfill Quality Assurance Aspects and get an insight into regulations such as United States Pharmacopeia (USP) and European Pharmacopoeia (Ph. Eur.)</strong></p>
</li>
<li><p><strong>Understanding of the Official Medicines Control Laboratory (OMCL) guidelines concerning the Karl Fischer oven system</strong></p>
</li>
</ul>
<blockquote>
<p><strong>Presenter:</strong> Bettina Straub-Jubb (Global Product Manager, Karl Fischer Titration at the life science business of Merck KGaA, Darmstadt, Germany)</p>
</blockquote>
<blockquote>
<p>Bettina is the Global Franchise Product Manager and lead expert for titration at Merck Life Science KGaA based in Darmstadt, Germany. She has more than 20 years’ experience in the instrumental analysis business, especially with Karl Fischer titration, general titration, reference materials, and diagnostics. Her responsibilities include improving and simplifying titration processes, driving new technologies, and advancing applications and reagents. She always works closely with the QC and application laboratories for titration as well as with the R&amp;D department to develop titration continuously. Bettina is a graduate engineer and holds a degree in Chemical Technology from the University of Applied Sciences, Darmstadt, Germany, and a degree as a Medical Technical Laboratory Assistant from the Medical Technical Academy Esslingen, Germany.</p>
</blockquote>
<blockquote>
<p><strong>Presenter:</strong> Thomas Hitz (Application Chemist, Mettler Toledo)</p>
</blockquote>
<blockquote>
<p>Thomas Hitz studied biochemistry at the University of Zurich and completed his PhD in 2003 at the Swiss Federal Institute of Technology Zurich in the Department of Material Sciences and Post Doctorate in 2006. He provides market support at Mettler Toledo and has more than 15 years&#39; experience in application development, sales, and customer training, and as a technical advisor for product development. He provides support for complex automation solutions and is an expert in automated Karl Fischer titration.</p>
</blockquote>


Separation Science: How to Fulfil Regulatory Compliance with Your Karl Fischer Titration Process

How to Fulfil Regulatory Compliance with Your Karl Fischer Titration Process

Karl Fischer titration process, quality assurance, and relevant regulations such as pharmacopeias to improve application accuracy.

Regulatory Compliance & Your Karl Fischer Titration Process

<p><strong>This webinar is your guide to get started with a fast and efficient, automated sample preparation protocol on the Opentrons OT-2.</strong></p>
<p>Utilize protein aggregation capture (PAC) on magnetic microparticles in an end-to-end  standardized and hands-off workflow, starting from protein lysate or plasma to peptide loaded on Evotips.</p>
<h4>Why choose an automated workflow?</h4>
<p>Automated sample preparation workflows have become a popular tool in proteomics laboratories for a number of reasons. With increased sample throughput on the Evosep One, you can prioritize numerous technical and biological replicates, adding robustness to downstream bioinformatic analyses.</p>
<p>By adopting full automation, you can gain precise control over protocols, ensuring reproducibility across samples and experiments. This minimizes batch effects, resulting in more reliable data for analysis and interpretation.</p>
<p>Furthermore, enhanced automation significantly reduces manual labor, enhancing reproducibility and providing researchers with more time for critical decision-making. This workflow also proves cost-efficient for large-scale applications, optimizing protein input for digestion.</p>
<h4>AUTOMATED WORKFLOW FOR INTEGRATED SAMPLE DIGESTION AND EVOTIP LOADING FOR HIGH-THROUGHPUT CLINICAL PROTEOMICS</h4>
<blockquote>
<p><strong>Presenter:</strong> Anders H.Kverneland (MD &amp; Postdoctoral researcher at Center for Cancer Immune Therapy, Herlev hospital)</p>
</blockquote>
<p>Protein identification and quantification is an important tool for biomarker discovery. With the increased sensitivity and shortened the analysis tim​e of modern mass spectrometers, sample-preparation remains a bottleneck and source of variability when studying large cohorts. To address this issue, we evaluated the use of a simple integrated workflow on the Opentrons OT-2 robot enabling both sample digestion and Evotip loading. Our results demonstrate high sensitivity combined with both reproducibility and stability even with very low sample inputs. The integration of the digestion and Evotip loading also strongly reduced the amount of reagents needed for the sample preparation. Using the integrated workflow, we evaluate the effects of cancer immune therapy on the plasma proteome in metastatic melanoma patients.</p>
<h4>STANDARDIZED AND FULLY AUTOMATED DEEP PROTEOME PROFILING OF PLASMA INTEGRATED WITH EVOSEP ONE ENABLES LARGE-SCALE CLINICAL COHORT ANALYSIS</h4>
<blockquote>
<p><strong>Presenter:</strong> Dorte Becker-Jensen (Application Manager at Evosep)</p>
</blockquote>
<p>This streamlined end-to-end workflow enables deep plasma profiling through the automated enrichment of membrane-bound vesicles and depletion of abundant proteins from a mere 4 μl of plasma. Integrated with the SCIEX ZenoTOF, it consistently identifies more than 3,500 protein groups, all with the ease of processing 30 samples per day at the push of a button.</p>


Evosep: Elevate efficiency: The power of automation

Elevate efficiency: The power of automation

Get started with a fast and efficient, automated sample preparation protocol on the Opentrons OT-2.

<p><strong>In this webinar, we will present end-to-end solutions for biopharma lab workflows with a focus on multiple mass spectrometry- based analysis techniques, ranging from SQ, TQ, TOF and Q-TOF.</strong></p>
<p>A broad portfolio in sample prep automation for protein therapeutics allows for highly reproducible results in the starting point of the analysis. A broad range of consumables and columns will be presented, leading into the subsequent separation via HPLC and detection by mass spectrometry.</p>
<p>The 6545XT AdvanceBio was particularly developed for intact protein analysis, and the ultra-high vacuum and large molecule autotune led to excellent sensitivity in denatured and native applications, allowing quantitation on the intact protein level as well as ADR calculations. Peptide mapping and glycan analysis results, along with the confirmation of oligonucleotide sequences using Q-TOF-based workflows, will be presented.</p>
<p>We will also highlight the ultrahigh performance of the novel 6495 triple quadrupole LC/MS system (G6495D) with MassHunter Workstation 12.1 for comprehensive multiplexed protein quantification. Artificial intelligence (AI)-based SWARM autotune and enhanced system features provide seamless protein quantification method optimization, ultimate analytical sensitivity, and high analytical precision as well as user-friendly instrument care and maintenance.</p>
<p>Lastly, we will show results from oligonucleotides and proteins analyzed on LC/MS single quadrupole and Time of Flight (TOF) instruments, the latest scientific applications, and recent method improvements.</p>
<blockquote>
<p><strong>Presenter:</strong> Ian Edwards, Ph.D. (LC/TQ Portfolio Product Manager, Agilent Technologies Inc.)</p>
</blockquote>
<blockquote>
<p>Ian holds a PhD from the Centre for Proteome Research at the University of Liverpool. He has spent time as a pre- and post-sales MS applications specialist focused on MS imaging and proteomics, as a field marketing manager for -omics, and as a global pharmaceutical marketing manager. Ian joined Agilent recently as LC/TQ Product Manager.</p>
</blockquote>
<blockquote>
<p><strong>Presenter:</strong> Russell Burge, Ph.D. (LC/SQ and LC/TOF Portfolio Product Manager, Agilent Technologies Inc.)</p>
</blockquote>
<blockquote>
<p>Russell earned a PhD in biochemistry and molecular biology from Scripps Research. He has extensive experience in the R&amp;D of biomolecules and biopharmaceuticals, and the implementation of automated workflows. Russell has acted as a Product Manager for various products in Life Science and Industrial Markets, and he currently manages the LC/MS SQ and LC/MS TOF product portfolios at Agilent.</p>
</blockquote>
<blockquote>
<p><strong>Presenter:</strong> Christian Klein, Ph.D. (LC/Q-TOF Portfolio Product Manager, Agilent Technologies Inc.)</p>
</blockquote>
<blockquote>
<p>With an education in Chemistry, Chris Klein received his Ph.D. in 2005 at the Max-Planck-Institute for Biochemistry in Martinsried, Germany. He joined Agilent Technologies in 2010 as the lead chemist in the LC/Q-TOF R&amp;D team. In 2018 Chris jointed the marketing team as Portfolio Product Manager, responsible for LC/Q-TOF and Ion Mobility.</p>
</blockquote>
<blockquote>
<p><strong>Presenter:</strong> Róisín Murtagh (Editor, Wiley)</p>
</blockquote>
<blockquote>
<p>Róisín Murtagh has been an editor for Wiley Analytical Science since 2021. She holds a science degree from Maynooth University, Ireland, and an MSc in Medicinal Chemistry from the Open University, UK. With a background encompassing over 10 years of experience in analytical science, she has actively contributed to both industry and academic research.</p>
</blockquote>


Wiley: Intelligent LC/MS tools for quantitation and characterization of biopharmaceuticals

Intelligent LC/MS tools for quantitation and characterization of biopharmaceuticals

End-to-end solutions for biopharma lab workflows with a focus on multiple mass spectrometry- based analysis techniques, ranging from SQ, TQ, TOF and Q-TOF.**

LC/MS quantitation & characterization of biopharmaceuticals

<p><strong>The recent success of mRNA vaccines demonstrates the capabilities of nucleic acid-based drugs. These new modalities hold the promise of delivering not only potent vaccines, but also enzyme replacement therapies. However, there is a need for more analytical characterization tools to provide more informationon stability, heterogeneity, drug design and structure-function relationships. Anion-exchange (AEX) and size exclusion (SEC) chromatography techniques are well suited to providing high resolution separations of nucleic acids and their carriers.</strong></p>
<p>AEX and SEC offer comprehensive quality and impurity profiling, but have suffered with previous methods from unsatisfactory recovery and resolution, poor MS compatibility. In addition, column hardware and packing materials have exhibited problematic secondary interactions. We have explored alternative mobile phase conditions in combination with various packing materials and sorbents in parallel with using novel low adsorption hardware allowing for more robust platform method for multiple drug substances and sample types, including AAVs and mRNA.</p>
<p>Learning Objectives Include:</p>
<ul>
<li><p><strong>Comprehensive overview of both theoretical and practical aspects of modern AEX and SEC separations.</strong></p>
</li>
<li><p><strong>New solutions and method parameter consideration for design of robust methods for nucleic acid separations.</strong></p>
</li>
<li><p><strong>Chromatography examples for small to very large nucleic acids</strong></p>
</li>
</ul>
<blockquote>
<p><strong>Presenter:</strong> Szabolcs Fekete PhD (R&amp;D Investigator, Waters Corporation)</p>
</blockquote>
<blockquote>
<p>Dr. Szabolcs Fekete worked as an analytical R&amp;D scientist in the pharmaceutical industry for 10 years then moved to the University of Geneva and worked as a scientific collaborator for a decade. In April 2021, he joined Waters Corporation and now works as one of the Chemistry department’s lead application and development scientists. . He has contributed to 200 pieces of published work.</p>
</blockquote>


Waters Corporation: New Insights on Anion Exchange and Size Exclusion of Nucleic Acids

New Insights on Anion Exchange and Size Exclusion of Nucleic Acids

We have explored alternative mobile phase conditions in combination with various packing materials and sorbents.

Anion Exchange and Size Exclusion of Nucleic Acids

<p><strong>We will examine how small changes to your vials &amp; closures can lead to a big impact to your recovery rates and reproducibility in your workflow.</strong></p>
<p>Let´s be realistic: you will never get 100% of your analyte out of your sample handling container but we can help to secure your valid sample and improve the accuracy of your results.</p>
<p>During this webinar, we will examine developments and tips to:</p>
<ul>
<li><strong>eliminate or at least reduce adsorption in an autosampler vial</strong></li>
<li><strong>reduce the risk of moving your analyte out of the target pks/pka value for reliable LC analysis</strong></li>
<li><strong>eliminate sample loss due to evaporation by poor seals</strong></li>
</ul>
<p>We hope you will leave this webinar with an understanding on how to identify small fixes to reduce or eliminate sample loss for significant improvements. The session will finish with a short Q&amp;A and include a live chat with an expert.</p>
<blockquote>
<p><strong>Presenter:</strong> Dr. Detlev Lennartz</p>
</blockquote>
<blockquote>
<p>Dr. Detlev Lennartz brings almost 30 years of experience in chromatography consumables (HPLC columns, GC columns, SPE cartridges, TLC products, and vials and closures). Twenty-four of those years he has been within product management developing and improving consumables for today’s researcher. His customer sales and technical support experience allows him to understand what challenges researchers face. The last twelve years Detlev has been the Thermo Scientific sample handling (autosampler vials, closures and well plates) worldwide product manager. Together, with a team of specialists, focusing on developing and launching new and innovative sample handling products, he hopes to share this knowledge to drive better efficiencies and improve results for researchers.</p>
</blockquote>


VWR: How to reduce your sample loss to significantly improve your results

How to reduce your sample loss to significantly improve your results

We will examine how small changes to your vials & closures can lead to a big impact to your recovery rates and reproducibility in your workflow.

How to reduce your sample loss to improve your results

<p><strong>Discover a new tool for multi projects search in Empower. This session shows you how you can use a new tool for answering questions that took a lot of effort in the past.</strong></p>


Waters Corporation: Waters Empower search tool

Empower search tool

This session shows you how you can use a new tool for answering questions that took a lot of effort in the past. 